Healthcare provider profile · identity verified

Girish Bulsara, MD FACP

Internal Medicine · NEW HYDE PARK, NY · NPI 1043298052

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	477	137
Amlodipine Besylate	Amlodipine Besylate	433	106
Eliquis	Apixaban	346	64
Levothyroxine Sodium	Levothyroxine Sodium	267	59
Furosemide	Furosemide	261	54
Lisinopril	Lisinopril	234	45
Pantoprazole Sodium	Pantoprazole Sodium	233	87
Gabapentin	Gabapentin	215	56
Sertraline Hcl	Sertraline Hcl	215	20
Metoprolol Succinate	Metoprolol Succinate	214	60
Losartan Potassium	Losartan Potassium	181	54
Tamsulosin Hcl	Tamsulosin Hcl	176	61
Metformin Hcl	Metformin Hcl	170	55
Donepezil Hcl	Donepezil Hcl	155	26
Metoprolol Tartrate	Metoprolol Tartrate	153	39
Famotidine	Famotidine	134	23
Januvia	Sitagliptin Phosphate	130	21
Carvedilol	Carvedilol	129	31
Potassium Chloride	Potassium Chloride	126	21
Mirtazapine	Mirtazapine	115	30
Hydralazine Hcl	Hydralazine Hcl	102	25
Quetiapine Fumarate	Quetiapine Fumarate	101	16
Levetiracetam	Levetiracetam	99	25
Memantine Hcl	Memantine Hcl	91	20
Pravastatin Sodium	Pravastatin Sodium	89	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	87	12
Clopidogrel	Clopidogrel Bisulfate	87	31
Finasteride	Finasteride	83	21
Latanoprost	Latanoprost	80	21
Baclofen	Baclofen	79	suppressed
Oxcarbazepine	Oxcarbazepine	79	13
Rosuvastatin Calcium	Rosuvastatin Calcium	76	23
Trazodone Hcl	Trazodone Hcl	70	13
Torsemide	Torsemide	67	suppressed
Omeprazole	Omeprazole	66	suppressed
Divalproex Sodium	Divalproex Sodium	65	16
Jardiance	Empagliflozin	61	16
Escitalopram Oxalate	Escitalopram Oxalate	58	16
Montelukast Sodium	Montelukast Sodium	55	13
Xarelto	Rivaroxaban	55	18
Nifedipine Er	Nifedipine	52	13
Memantine Hcl Er	Memantine Hcl	51	suppressed
Mupirocin	Mupirocin	50	14
Doxazosin Mesylate	Doxazosin Mesylate	49	suppressed
Valsartan	Valsartan	46	suppressed
Alendronate Sodium	Alendronate Sodium	43	16
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	42	12
Atenolol	Atenolol	41	suppressed
Olanzapine	Olanzapine	41	suppressed
Simvastatin	Simvastatin	41	16
Albuterol Sulfate Hfa	Albuterol Sulfate	40	20
Brimonidine Tartrate	Brimonidine Tartrate	40	suppressed
Novolog Flexpen	Insulin Aspart	39	11
Entresto	Sacubitril/Valsartan	36	suppressed
Enalapril Maleate	Enalapril Maleate	35	suppressed
Bupropion Xl	Bupropion Hcl	34	suppressed
Oxycodone Hcl	Oxycodone Hcl	34	31
Glipizide Er	Glipizide	33	suppressed
Midodrine Hcl	Midodrine Hcl	32	12
Ranolazine Er	Ranolazine	32	suppressed
Tramadol Hcl	Tramadol Hcl	32	31
Aripiprazole	Aripiprazole	29	suppressed
Budesonide Dr	Budesonide	29	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	29	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	29	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	27	suppressed
Bupropion Hcl Sr	Bupropion Hcl	27	suppressed
Duloxetine Hcl	Duloxetine Hcl	27	11
Rivastigmine	Rivastigmine	27	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	26	suppressed
Mesalamine Er	Mesalamine	26	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	26	suppressed
Gemtesa	Vibegron	25	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	25	14
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Carbamazepine Er	Carbamazepine	23	suppressed
Tivicay	Dolutegravir Sodium	23	suppressed
Tradjenta	Linagliptin	23	suppressed
Meloxicam	Meloxicam	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Albuterol Sulfate	Albuterol Sulfate	21	suppressed
Lubiprostone	Lubiprostone	21	suppressed
Prezcobix	Darunavir/Cobicistat	20	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	suppressed
Santyl	Collagenase Clostridium Hist.	19	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Bumetanide	Bumetanide	18	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	18	suppressed
Solifenacin Succinate	Solifenacin Succinate	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Divalproex Sodium Er	Divalproex Sodium	16	suppressed
K-Phos No.2	Sod Phos,m-B/K Phos,monob	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Labetalol Hcl	Labetalol Hcl	15	suppressed
Acetylcysteine	Acetylcysteine	14	suppressed
Calcitriol	Calcitriol	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Timolol Maleate	Timolol Maleate	14	suppressed
Travoprost	Travoprost	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Allopurinol	Allopurinol	13	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	suppressed
Enulose	Lactulose	13	suppressed
Haloperidol	Haloperidol	13	suppressed
Rhopressa	Netarsudil Mesylate	13	suppressed
Anastrozole	Anastrozole	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Nystop	Nystatin	12	suppressed
Acetazolamide Er	Acetazolamide	11	suppressed
Amantadine	Amantadine Hcl	11	suppressed
Azithromycin	Azithromycin	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Folic Acid	Folic Acid	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed
Phenobarbital	Phenobarbital	11	suppressed
Prednisone	Prednisone	11	suppressed
Ssd	Silver Sulfadiazine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error